Skip to Main Content

Paper Details

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Cell Rep Med
17
2022
/Ig sequences, B cell, BCB, DNA, Ig, RNA, T cell, TCR, TMB, genomes, immune- and tumor-expressed genes, lymphocyte, melanoma, patients, rearranged TCR, transcriptomes, tumor, tumor-infiltrating T cells, tumors
Author NameAffiliation
Samuel S FreemanBroad Institute of MIT and Harvard
Samuel S FreemanHarvard Medical School
Samuel S FreemanBroad Institute of MIT and Harvard
Samuel S FreemanHarvard Medical School
Jaegil KimBroad Institute of MIT and Harvard
Chip StewartBroad Institute of MIT and Harvard
Chip StewartBroad Institute of MIT and Harvard
Arvind RaviBroad Institute of MIT and Harvard
Arvind RaviDana-Farber Cancer Institute
Keren YizhakTechnion - Israel Institute of Technology
Ignaty LeshchinerBroad Institute of MIT and Harvard
Ignaty LeshchinerCenter for Cancer Research, Massachusetts General Hospital
Dimitri LivitzBroad Institute of MIT and Harvard
Daniel RosebrockBroad Institute of MIT and Harvard
François AguetBroad Institute of MIT and Harvard
Stacey GabrielBroad Institute of MIT and Harvard
Stacey GabrielBroad Institute of MIT and Harvard
Anat Stemmer-RachamimovMassachusetts General Hospital
Jennifer A WargoUniversity of Texas MD Anderson Cancer Center
Matthew MeyersonBroad Institute of MIT and Harvard
Matthew MeyersonHarvard Medical School
Matthew MeyersonDana-Farber Cancer Institute
Matthew MeyersonBroad Institute of MIT and Harvard
Matthew MeyersonDana-Farber Cancer Institute
Matthew MeyersonHarvard Medical School
Gad GetzBroad Institute of MIT and Harvard
Gad GetzHarvard Medical School
Gad GetzHarvard University
Gad GetzCenter for Cancer Research, Massachusetts General Hospital
Gad GetzBroad Institute of MIT and Harvard
Gad GetzCenter for Cancer Research, Massachusetts General Hospital
Gad GetzHarvard University
Gad GetzHarvard Medical School
Nir HacohenBroad Institute of MIT and Harvard
Nir HacohenCenter for Cancer Research, Massachusetts General Hospital
Nir HacohenHarvard Medical School
Nir HacohenBroad Institute of MIT and Harvard
Nir HacohenCenter for Cancer Research, Massachusetts General Hospital
Nir HacohenHarvard Medical School
  • 1 - 39

Datasets

Release 1.2